U.S. patent No. 10,829,738 covers methods for producing gene-edited cells using mRNA encoding TALENs. This patent, and the other patent (No. 10,662,410) awarded to Factor by the U.S. Patent and Trademark Office, form the foundation of clinical-stage allogeneic chimeric antigen receptor (CAR) T-cell therapies, according to the company. Their methods are used to inactivate the endogenous T-cell receptor to prevent therapeutic T cells from causing graft-versus-host disease (GvHD) and to perform other key cell engineering steps, Factor said.

Factor Bioscience GA-15 mRNA vectorization. Image courtesy of Factor Bioscience.

In addition, these patented methods are also used in applications such as generation of allogeneic stem cell-derived therapies. In these treatments, mRNA encoding TALENs are used to inactivate components of the human leukocyte antigen (HLA) complex to render the cells immuno-nonreactive and to insert donor sequences into defined genomic loci to enable controlled expression of exogenous genes, according to the company.

Other patents are currently pending in the U.S. and other countries, Factor said.

Poseida CAR T clinical trial hold lifted
The U.S. Food and Drug Administration has lifted a clinical trial hold on Poseida Therapeutics' phase I study of P-PSMA-101, an autologous chimeric antigen...

Gracell secures funding to advance CAR T therapies
Gracell Biotechnologies has secured $100 million in series C funding to expand its chimeric antigen receptor (CAR) T-cell therapies.

A 'Pac-Man' like CRISPR system could enable larger gene edits
A new CRISPR tool utilizes Cas3 to remove larger than normal stretches of DNA both quickly and accurately. The tool, described in an October 19 article...

Moderna gets nod from EMA to submit marketing authorization
Moderna has received written confirmation from the European Medicines Agency (EMA) that messenger RNA (mRNA)-1273, the company's COVID-19 vaccine candidate,...